Adalimumab levels detected in cord blood and infants exposed in utero

Adalimumab (ADA), a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers at the University of California San Francisco have found.

Read the whole article on Physorg

More from Physorg